AWM
RXRX icon

Axxcess Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Axxcess Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
38,768
+1,252
+3% +$4.17K ﹤0.01% 1027
2026
Q1 		$115K Buy
37,516
+5,338
+17% +$20.6K ﹤0.01% 371
2025
Q4 		$132K Buy
32,178
+1,378
+4% +$6.83K ﹤0.01% 1016
2025
Q3 		$150K Sell
30,800
-10,025
-25% -$52.6K ﹤0.01% 906
2025
Q2 		$207K Buy
40,825
+510
+1% +$2.5K ﹤0.01% 837
2025
Q1 		$213K Sell
40,315
-825
-2% -$6.01K 0.01% 794
2024
Q4 		$278K Sell
41,140
-2,744
-6% -$18.4K 0.01% 691
2024
Q3 		$289K Buy
43,884
+1,795
+4% +$12.9K 0.01% 698
2024
Q2 		$316K Buy
42,089
+4,704
+13% +$41K 0.01% 634
2024
Q1 		$373K Buy
37,385
+14,388
+63% +$160K 0.01% 610
2023
Q4 		$227K Buy
+22,997
New +$164K 0.01% 739

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Axxcess Wealth Management's RXRX Position: Q2 2026 in Review

Axxcess Wealth Management increased its Recursion Pharmaceuticals (RXRX) stake by 3.3% in Q2 2026, buying an estimated $4.17K and bringing the position to 38,768 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #1027.

Axxcess Wealth Management first reported a position in RXRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $373K in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Axxcess Wealth Management held 38,768 shares of Recursion Pharmaceuticals worth $142K as of Q2 2026.
  • Axxcess Wealth Management bought 1,252 Recursion Pharmaceuticals shares in Q2 2026, an estimated $4.17K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Axxcess Wealth Management's portfolio in Q2 2026, its #1027 holding.
  • Axxcess Wealth Management first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Axxcess Wealth Management's Recursion Pharmaceuticals position peaked at $373K in Q1 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Axxcess Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.